AI Tool Predicts Inherited Breast Cancer Risk From Family History
Studies an AI tool using family cancer history to predict breast cancer genetic risk.
Plain-language title generated from the registry record
Registry title: Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer
Key facts
- Where
- Golania and Porto Alegre, BrazilSee the 2 sites
Where in Brazil
- GolaniaGolania, BrazilNo longer taking part
- Porto AlegrePorto Alegre, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07070128
- Record updated
- 29 July 2026
- Original description
It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.Read full original descriptionShow less
Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer (STAR-BREAST)
It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.
Inclusion: female patients,; aged 18 years or older,; identified as high genetic risk by breast surgeons,; referred to a geneticist, and; who agree to participate in the study.
Exclusion: male patients,; absence of complete information in the medical records,; patients unaware of their biological family history, and; patients who do not agree to participate in the study.